BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21963359)

  • 1. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.
    Walsh S; Flanagan L; Quinn C; Evoy D; McDermott EW; Pierce A; Duffy MJ
    Breast; 2012 Apr; 21(2):178-82. PubMed ID: 21963359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytologic features of triple-negative breast carcinoma.
    Bonzanini M; Morelli L; Bonandini EM; Leonardi E; Pertile R; Dalla Palma P
    Cancer Cytopathol; 2012 Dec; 120(6):401-9. PubMed ID: 22833438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.
    Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
    Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
    Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
    Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
    J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
    Yu J; Gao F; Klimberg VS; Margenthaler JA
    Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.